Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Mylan’s Voluntary EpiPen Recall Now Includes US

XTALKS VITALS NEWS

EpiPen

According to Mylan, the potentially defective auto-injectors may fail to activate in an emergency.

Share this!

April 4, 2017 | by Sarah Hand, M.Sc.

Meridian Medical, a Pfizer-owned company and Mylan’s manufacturing partner for the EpiPen, has expanded its recall of the medical device to include lots distributed in the US. The decision to expand the recall of the epinephrine auto-injectors was based on a meeting with the US Food and Drug Administration (FDA).

According to Mylan, the potentially defective auto-injectors may fail to activate in an emergency. Because the combination drug/device is used to treat patients experiencing a life-threatening allergic reaction, the consequences of having a nonfunctional auto-injector could be fatal.

In March, Mylan issued its first recall of specific batches of the EpiPen, which were distributed in New Zealand, Australia, Japan and Europe. The recall was initiated following reports that two EpiPens had failed to activate.

The initial recall affected a batch of approximately 80,000 medical devices. Now that Mylan and Meridian have expanded this voluntary recall to include 13 additional batches, the number of potentially affected devices is likely much higher.



The potentially defective auto-injectors include batches of both the EpiPen 2-Pak and EpiPen Jr 2-Pak, however no authorized generic versions are affected at this time. In addition to some batches in the US being affected by the recall, patients in other parts of North America, South America, Europe and Asia, may also be in possession of affected auto-injectors.

“Mylan is committed to replacing recalled devices at no cost and Mylan would like to reassure patients that there will be no additional replacement-related financial burden to them as a result of this recall,” said the Mylan press release on the expanded recall. “We are asking patients to keep their existing product until their replacement product can be secured.”

This recall is just the latest in a string of bad press for Mylan. Since 2016, the company has been facing scrutiny over its pricing practices for the EpiPen, which has risen in price to over $600 for a two-pack. Generic competitors – like Impax Pharmaceuticals’ Adrenaclick – are also increasingly looking to secure some of Mylan’s market share for the medical device.


Keywords:  EpiPen, Medical Device, Combination Product


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
German Merck Launches Spinoff Immuno-Oncology Company

June 22, 2017 - Merck KGaA has announced the launch of iOnctura SA, a new immuno-oncology company built around two assets from the Healthcare R&D portfolio of the pharmaceutical company.

Featured In: Biotech News


Ikea Promotes Food Products by Offering Fill-in-the-Blanks Recipe Sheets

June 21, 2017 - In an effort to promote the company’s food business, Ikea recently launched a set of recipes printed on parchment paper that encourage consumers to “fill-in-the-blanks” with ingredients, fold the paper and cook the bag in the oven.

Featured In: Food News


Nanomaterial Promotes Bone Growth after Spinal Fusion Surgery

June 21, 2017 - Researchers at Northwestern University have developed a bioactive nanomaterial capable of effectively stimulating bone regeneration after spinal fusion surgery.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Drug Development During the Last Week

REGISTER FOR THESE WEBINARS

Serialized? Yes. But are Products Still Being Diverted?


Quantitative Protein Profiling in FFPE to Characterize Toxicities Associated with Immune Checkpoint Inhibitors


Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model


Imaging-based Subtypes of Pancreatic Cancer


Copyright © 2016-2017 Honeycomb Worldwide Inc.